Kelly on a heated day at the FDA and why a new drug class could bring diabetes patients, doctors, and educators closer to personalized therapy.
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
37 readers recommended
On March 1, Vivus started its Save Now! program, which sets a discounted price of $75 for one 30-day supply of the company’s weight management medication Qsymia (7.5 mg...
40 readers recommended
On June 27, the FDA approved Arena Pharmaceutical’s weight-loss drug Belviq (lorcaserin), the first weight-loss drug to be approved in the US in 13 years. Belviq is...
50 readers recommended
On August 29, J&J’s chronic pain drug Nucynta ER (tapentadol) was granted FDA approval for the management of the pain associated with diabetic peripheral neuropathy...
48 readers recommended
On January 11, an advisory panel recommended that the FDA approve Johnson & Johnson’s SGLT-2 inhibitor, Invokana (canagliflozin). The panel voted 10-5 in favor of...
22 readers recommended
Kelly reflects on a major advance in obesity treatment and highlights a memorable day for diabetes at the Major League Baseball Hall of Fame.
47 readers recommended
The 30th Annual Obesity Society Meeting brings exciting insights on drugs and mobile health.
34 readers recommended
Dr. Sanjay Kaul speaks to diaTribe about the new SGLT-2 drug class.
42 readers recommended
On July 17, the FDA approved Vivus’ weight-loss medication Qsymia (formerly called Qnexa), just several weeks after the approval of Arena’s Belviq (see new now next in...
70 readers recommended
What’s an SGLT-2 inhibitor and how does it work? Includes cool FAQ!
57 readers recommended
In June, pharmaceutical giant Bristol-Myers Squibb (BMS) and its partner AstraZeneca (AZ) acquired the important biotech company Amylin for a cool $7 billion, which we...
47 readers recommended
On November 8, an FDA advisory panel voted 8-4 to recommend approval of Novo Nordisk’s ultra-long-acting basal insulin degludec (to be marketed under the name “Tresiba...
57 readers recommended
Can a drug for type 2 diabetes work for those with type 1? How will a new basal insulin compare to Lantus?
36 readers recommended
Dr. Arya Sharma highlights the most important weight loss tip everyone should know and why weight maintenance is a major achievement.
56 readers recommended
The past few months have seen the approval of a pair of new drugs designed to treat obesity, Arena’s Belviq (see new now next in diaTribe #44) and Vivus’ Qsymia (see new...
26 readers recommended
How can the FDA change its view on drug approvals to give patients access to better therapies?
30 readers recommended
Many people with diabetes fear eye diseases leading to blindness. In diabetic macular edema (DME), the leading cause of blindness among working-age Americans (over 560,...
50 readers recommended
In late November, Vivus launched its Get Started! Program , which gives potential users of its weight management medication Qsymia a chance to try the drug free for two...
37 readers recommended
On February 8, Novo Nordisk received an FDA complete response letter (CRL) for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/aspart). Tresiba is Novo Nordisk’...